Bristol-Myers Squibb plans to acquire Celgene for $74 billion in one of history's biggest mergers of pharmaceutical companies. Celgene and BMS have successful cancer drugs on the market in Opdivo and Revlimid.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.